Fluclotizolam

In the wide world of Fluclotizolam, we find a diversity of aspects and approaches that invite us to explore and understand further. From its impact on contemporary society to its relevance in history, Fluclotizolam has been the subject of numerous debates and reflections. In this article, we will delve into the different facets of Fluclotizolam, highlighting its importance and influence in different fields. Through a detailed analysis, we will explore the implications and consequences linked to Fluclotizolam, with the aim of providing a complete and enriching vision of this fascinating topic.

Fluclotizolam
Legal status
Legal status
Identifiers
  • 2-chloro-4-(2-fluorophenyl)-9-methyl-4H-thieno triazolo diazepine
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC15H10ClFN4S
Molar mass332.78 g·mol−1
3D model (JSmol)
  • Fc4ccccc4C2=NCc1nnc(C)n1c3sc(Cl)cc23
  • InChI=1S/C15H10ClFN4S/c1-8-19-20-13-7-18-14(9-4-2-3-5-11(9)17)10-6-12(16)22-15(10)21(8)13/h2-6H,7H2,1H3
  • Key:ZDYRCUZZLRLMHG-UHFFFAOYSA-N

Fluclotizolam is a thienotriazolodiazepine derivative which was first synthesised in 1979, but was never marketed. It has subsequently been sold as a designer drug, first being definitively identified in 2017.

See also

References

  1. ^ US 4155913, Hellerbach J, Zeller P, Binder D, Hromatka O, "Thienotriazolodiazepine derivatives.", issued 22 May 1979, assigned to Hoffmann La Roche Inc 
  2. ^ Zawilska JB, Wojcieszak J (July 2019). "An expanding world of new psychoactive substances-designer benzodiazepines". Neurotoxicology. 73: 8–16. doi:10.1016/j.neuro.2019.02.015. PMID 30802466. S2CID 73461430.
  3. ^ Moosmann B, Auwärter V (2018). "Designer Benzodiazepines: Another Class of New Psychoactive Substances.". In Maurer H, Brandt S (eds.). New Psychoactive Substances. Handbook of Experimental Pharmacology. Vol. 252. pp. 383–410. doi:10.1007/164_2018_154. ISBN 978-3-030-10560-0. PMID 30367253.
  4. ^ Chetraru E, Ameline A, Gheddar L, Raul JS, Kintz P (February 2018). "Les designer benzodiazepines: qu'en sait-on aujourd'hui?". Toxicologie Analytique et Clinique. 30 (1): 5–18. doi:10.1016/j.toxac.2017.12.001.
  5. ^ Orsolini L, Corkery JM, Chiappini S, Guirguis A, Vento A, De Berardis D, et al. (2020). "'New/Designer Benzodiazepines': An Analysis of the Literature and Psychonauts' Trip Reports". Current Neuropharmacology. 18 (9): 809–837. doi:10.2174/1570159X18666200110121333. PMC 7569319. PMID 31933443.
  6. ^ Catalani V, Botha M, Corkery JM, Guirguis A, Vento A, Scherbaum N, Schifano F (July 2021). "The Psychonauts' Benzodiazepines; Quantitative Structure-Activity Relationship (QSAR) Analysis and Docking Prediction of Their Biological Activity". Pharmaceuticals. 14 (8): 720. doi:10.3390/ph14080720. PMC 8398354. PMID 34451817.
  7. ^ Catalani V, Floresta G, Botha M, Corkery JM, Guirguis A, Vento A, et al. (January 2023). "In silico studies on recreational drugs: 3D quantitative structure activity relationship prediction of classified and de novo designer benzodiazepines". Chemical Biology & Drug Design. 101 (1): 40–51. doi:10.1111/cbdd.14119. hdl:2299/25749. PMID 35838189. S2CID 250559695.
Wikious
Boobota
Sagapedia